Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New analysis shows the lower range of the licensed dose of the most commonly used second-generation antidepressants achieves the optimal balance between efficacy, tolerability and acceptability in the acute treatment of adults with major depression.

This new study, Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis, was published in The Lancet Psychiatry.It demonstrates important clinical implications for guidelines and the daily use of antidepressants in real world settings.

The study focused on the most frequently prescribed antidepressants in the UK, including five SSRIs (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, paroxetine and sertraline), venlafaxine and mirtazapine. Data from 19,364 participants was used to assess efficacy, acceptability and tolerability over a median of 8 weeks treatment.

Optimal acceptability and dose-efficacy for the SSRIs was in the lower licensed range between 20 mg and 40mg fluoxetine equivalents. For both venlafaxine and mirtazapine optimal acceptability was also in the lower range of their licensed dose. However, for venlafaxine efficacy was increasing up to 150 mg and for mirtazapine dose-efficacy increased only up to about 30 mg.

When I see patients in my clinic and we agree on prescribing an antidepressant for their depressive episode, the big challenge is not only to prescribe the right medication but also to find the best dosage for each individual, optimising efficacy and reducing side effects. Current practice guidelines provide conflicting recommendations. - Professor Andrea Cipriani, Dept of Psychiatry

In the UK the NICE (National Institute for Clinical Excellence) guidelines state that there is no dose dependency within the therapeutic range of SSRIs, in the US guidelines from the American Psychiatric Association recommend slow titration up to the maximum tolerated dose. This new evidence suggests neither of these methods are correct.

The study was carried out by an international team of experts led by the University of Oxford and was funded by the National Institute for Health Research in the UK, together with the Japan Society for the Promotion of Science and the Swiss National Science Foundation.

Similar stories

How to use the science of the body clock to improve our sleep and health

Professor Russell Foster has written a new book about circadian neuroscience which is published by Penguin this week. This book review by Jacqueline Pumphrey was first published on the University of Oxford website.

NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills

Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said.

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Developmental dynamics of the neural crest–mesenchymal axis in creating the thymic microenvironment

A new paper from researchers at the Department of Paediatrics and the Nuffield Department of Clinical Neurosciences has shown that fibroblasts in the thymus, often considered simply as dull “structural” cells, are much more complex than previously thought.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.